{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/osteoarthritis/prescribing-information/topical-nsaids/","result":{"pageContext":{"chapter":{"id":"3c945e6b-1050-57b1-8fb2-52d4675e3b20","slug":"topical-nsaids","fullItemName":"Topical NSAIDs","depth":2,"htmlHeader":"<!-- begin field 7222aa4e-f1a0-4f80-be2b-a77500cde29a --><h2>Topical NSAIDs</h2><!-- end field 7222aa4e-f1a0-4f80-be2b-a77500cde29a -->","summary":"","htmlStringContent":"<!-- begin item 204d1af5-6f98-45cf-95f3-a77500cde09c --><!-- end item 204d1af5-6f98-45cf-95f3-a77500cde09c -->","topic":{"id":"de61cfe3-a7fc-50bd-87eb-af7e90b20bfc","topicId":"c9866707-687c-4314-bff3-ae71e0d7e669","topicName":"Osteoarthritis","slug":"osteoarthritis","lastRevised":"Last revised in June 2018","chapters":[{"id":"9674ea7a-b052-5c2f-a0a1-336c67e0622a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"aec2334e-8ee7-5d04-902e-c9a904550f17","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6a895bdb-e3ce-53e5-a302-6bbca48a6e9f","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"5ae3cd70-eacb-5c4c-98f5-dace0da22472","slug":"changes","fullItemName":"Changes"},{"id":"2723ad88-c2c8-5b92-ac37-5d5af66e900a","slug":"update","fullItemName":"Update"}]},{"id":"3ffc0128-f379-5b16-bfbb-fe9c04753b07","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"740484d6-e553-5d2a-bcbf-22e4b61e30c8","slug":"goals","fullItemName":"Goals"},{"id":"2ab52642-cd7c-5b7d-a3c9-911580e1911c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3bb32b14-2fda-58fa-b09c-cd98270c7adb","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"35eeb6be-f0dd-5cde-a148-b87e5da25be5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3a253c38-1fe5-581e-8eff-eb2e5225d071","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"06733eae-d1c5-59d1-a725-266721a216af","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3825aa8e-f0d5-5c9c-89b4-1898289f4fc9","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"182bd361-b277-56da-ba91-aec64a5dbc1e","slug":"definition","fullItemName":"Definition"},{"id":"8696aed8-8dba-5a61-a12d-83015e11e6f3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"80accb52-81a2-5799-93cd-5e7582f72276","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"c1ea97e2-1426-5b7d-bde9-716cb3c7eafa","slug":"complications","fullItemName":"Complications"},{"id":"274efaa2-3e84-556a-b637-e3465e12e5e3","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"27d93353-f59d-560a-a997-442790b4886e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"fb6bb640-6ea0-5e5d-ab1e-226ba7b3f1a5","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"3946b5ad-ac52-5fa8-aac6-2336526f17d7","slug":"assessment","fullItemName":"Assessment"},{"id":"258c85c0-fccc-5104-bd56-7b9ad61740f0","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"431a0217-fdab-502e-926c-a37e20150d61","fullItemName":"Management","slug":"management","subChapters":[{"id":"281a0a54-9420-5c71-ab29-0e6ac788fdb5","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"157c78c6-0823-59f1-be8e-37716aebc131","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"3c945e6b-1050-57b1-8fb2-52d4675e3b20","slug":"topical-nsaids","fullItemName":"Topical NSAIDs"},{"id":"7859a51d-1efc-5b71-8547-74135120e0c1","slug":"topical-capsaicin","fullItemName":"Topical capsaicin"}]},{"id":"605232dc-8685-5f88-b393-460b958a4e26","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"376de13c-5458-5bd0-987d-d1998635c19a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"098b9a8a-7356-5cc6-8d8e-103f9f4b5c19","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"114aa4f2-a690-5db8-913f-ed5733b88ec7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c4a226d2-7bc7-5f71-822a-bb2115a1e0da","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f5a772c1-6d28-5056-becd-1d1b06be8907","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c56a97ce-4c02-5076-a99e-b3272c1e9bd4","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7ad7c476-7017-5c96-bd7d-25890a8b6390","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"157c78c6-0823-59f1-be8e-37716aebc131","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"0dae68ea-e02c-57e0-9026-65464554b871","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 7c9ea3a3-f714-41b2-85c7-a8ff0150a28b --><h3>Contraindications and cautions</h3><!-- end field 7c9ea3a3-f714-41b2-85c7-a8ff0150a28b -->","summary":"","htmlStringContent":"<!-- begin item 7aa0a7ee-c9f3-4e17-aa6a-a8ff01509f44 --><!-- begin field b4ac5d55-3802-442a-af5a-a8ff0150a28f --><p><strong>Prescribe topical NSAIDs with caution:</strong></p><ul><li>Avoid contact with the eyes, inflamed or broken skin, and mucous membranes.</li><li>Do not use with occlusive dressings.</li><li>Be aware that application of large amounts can result in systemic effects, including hypersensitivity, asthma, and possible renal disease.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoarthritis/references/\">BNF 75, 2018</a>]</p><!-- end field b4ac5d55-3802-442a-af5a-a8ff0150a28f --><!-- end item 7aa0a7ee-c9f3-4e17-aa6a-a8ff01509f44 -->","subChapters":[]},{"id":"985e3b7f-79de-588e-abec-39fe5541f0b6","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 8e0201dc-ff86-45ea-a334-a8ff0150c729 --><h3>Adverse effects</h3><!-- end field 8e0201dc-ff86-45ea-a334-a8ff0150c729 -->","summary":"","htmlStringContent":"<!-- begin item 270fa7a6-0be8-4481-9e1c-a8ff0150c5f4 --><!-- begin field e4e6c487-0709-4831-888a-a8ff0150c729 --><p><strong>Adverse effects of topical NSAIDs may include:</strong></p><ul><li>Skin photosensitivity and rash — discontinue use if rash develops.</li><li>Possible systemic effects, including hypersensitivity, asthma, and renal disease — may occur if large quantities are applied. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a> for more information.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoarthritis/references/\">BNF 75, 2018</a>] </p><!-- end field e4e6c487-0709-4831-888a-a8ff0150c729 --><!-- end item 270fa7a6-0be8-4481-9e1c-a8ff0150c5f4 -->","subChapters":[]},{"id":"90810606-5a09-5a62-8ff2-273a6d519354","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 9d5c9c47-5152-4c1b-88eb-a8ff0150db57 --><h3>Drug interactions</h3><!-- end field 9d5c9c47-5152-4c1b-88eb-a8ff0150db57 -->","summary":"","htmlStringContent":"<!-- begin item ba7caf11-14a4-457b-812a-a8ff0150da89 --><!-- begin field 47446e7f-345e-4b07-b6f7-a8ff0150db57 --><ul><li>Be aware that systemic absorption may follow topical application, and the possibility of drug interactions should be considered. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a> for more information.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoarthritis/references/\">BNF 75, 2018</a>] </p><!-- end field 47446e7f-345e-4b07-b6f7-a8ff0150db57 --><!-- end item ba7caf11-14a4-457b-812a-a8ff0150da89 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}